PATENT CLAIM ANALYSIS

Application Number: 16072686
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-06
Patent Classification: ["514", "471000"]

Abstract:
The use of an NLRP3 inhibitor compound is described in the treatment of inflammatory skin disorders, in particular psoriasis and atopic dermatitis.

Claim (Index 21):
A method for treating an inflammatory skin disorder, comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof: wherein:\n X represents a group C\u2014R 1  or a nitrogen atom; \n R 1  represents a hydrogen atom or a halogen; \n R 2 , R 3 , R 4  and R 5  independently represent a hydrogen atom or a C 1 -C 6  alkyl, R 2  and R 3  taken together can form a cyclopentyl with the carbon atoms of the phenyl to which they are bonded, and R 4  and R 5  taken together can form a cyclopentyl with the carbon atoms of the phenyl to which they are bonded; and \n Ar represents a group selected from the group consisting of: \n and a pharmaceutically acceptable carrier.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 99.0
- Lexical Diversity: 1.09091
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15551264', '14380078', '12992766', '10559322', '12937006']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7435259053764748
- 35 USC 102 Novelty (BERT): 0.5016074324227668
- Combined Prediction Score: 0.7193340580811041
- Mean Citation Score: 225.059508
- Max Citation Score: 256.63382
- Similarity Product: 187.0451599569881

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test